https://www.gosh.nhs.uk/our-people/staff-z/james-davison/

James Davison

Dr James davison

Dr Davison has been part of the Great Ormond Street Hospital (GOSH) metabolic team since 2012, having previously trained and worked in Birmingham/West Midlands.

He has a particular interest in lysosomal disorders but sees patients with all general metabolic disorders. His research work currently focusses on development of new treatments for Pompe disease and Hunter Syndrome (MPS II). He is a member of the GOSH Drugs and Therapeutics Committee (DTC) and has supported NICE as a Clinical Expert in the evaluation of several recently approved novel treatments.

Dr Davison has a focus on education and training and is on the Society for the Study of Inborn Errors of Metabolism (SSIEM) Education and Training Committee. He is also the current Chair of the British Inherited Metabolic Diseases Group (BIMDG).

Specialisms

  • General metabolic medicine
  • Lysosomal storage disorders
  • Pompe disease

Publications

  1. Davison JE. Mucopolysaccharidosis type III. In Lysosomal Storage Disorders: A Practical Approach, 2nd edition. In press
  2. Davison JE, Humphries S, Winchester B, Mole SE. Prenatal Diagnosis of Disorders of Lipid Metabolism. In Genetic disorders and the fetus: diagnosis, prevention and treatment, 8th edition.
  3. Davison JE. Advances in diagnosis and management of Pompe disease. J Mother Child 2020;24(2):3-8.
  4. Davison JE. Eye involvement in inherited metabolic disorders. Ther Adv Ophthalmol 2020; doi:10.1177/2515841420979109
  5. Cleary M, Davison J, Gould R, Geberhiwot T, Hughes D, Mercer J, Morrison A, Murphy E, Santra S, Jarrett J, Mukherjee S, Stepien KM. Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England. Orphanet J Rare Dis. 2021 Jan 21;16(1):38.